Holen Sie sich die Stockscreener-App
6.87
4.18%
-0.30
Handel nachbörslich:
6.97
0.10
+1.46%
Schlusskurs vom Vortag:
$7.17
Offen:
$7.12
24-Stunden-Volumen:
1.62M
Relative Volume:
1.75
Marktkapitalisierung:
$741.95M
Einnahmen:
$247.00M
Nettoeinkommen (Verlust:
$-249.00M
KGV:
-2.2233
EPS:
-3.09
Netto-Cashflow:
$-267.00M
1W Leistung:
-15.91%
1M Leistung:
-29.10%
6M Leistung:
-58.74%
1J Leistung:
-60.22%
1-Tages-Spanne:
$6.79
$7.31
1-Wochen-Bereich:
$6.79
$8.02
52-Wochen-Spanne:
$6.79
$18.98
Arcus Biosciences Inc Stock (RCUS) Company Profile
Firmenname
Arcus Biosciences Inc
Sektor
Branche
Telefon
(510) 694-6200
Adresse
3928 POINT EDEN WAY, HAYWARD, CA
Vergleichen Sie RCUS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
6.87 | 741.95M | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-26 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-10-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2020-04-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-09-27 | Eingeleitet | Mizuho | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2018-10-09 | Eingeleitet | Wedbush | Outperform |
| 2018-04-09 | Eingeleitet | Citigroup | Buy |
| 2018-04-09 | Eingeleitet | Goldman | Neutral |
| 2018-04-09 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Arcus Biosciences Inc Aktie (RCUS) Neueste Nachrichten
RCUS stock touches 52-week low at $7.5 amid market challenges - Investing.com
RCUS stock touches 52-week low at $7.5 amid market challenges By Investing.com - Investing.com South Africa
Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts - Seeking Alpha
(RCUS) Trading Signals - news.stocktradersdaily.com
Institutional owners may consider drastic measures as Arcus Biosciences, Inc.'s (NYSE:RCUS) recent US$134m drop adds to long-term losses - simplywall.st
Arcus Biosciences, Inc.'s (NYSE:RCUS) latest 8.6% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo Finance
Arcus Biosciences Announces New Employment Inducement Grants - Bluefield Daily Telegraph
RCUS stock touches 52-week low at $8.81 amid market challenges - Investing.com
Cancer Therapy Pioneer Arcus Biosciences Accelerates Growth with Key Team Expansion - Stock Titan
RCUS stock touches 52-week low at $8.97 amid market challenges - Investing.com Australia
RCUS stock touches 52-week low at $8.97 amid market challenges By Investing.com - Investing.com South Africa
Arcus Biosciences, Inc. (RCUS): Among Top Insider Purchases Last Month - Insider Monkey
RCUS FY2025 EPS Estimate Raised by Cantor Fitzgerald - Defense World
Arcus Biosciences at Barclays Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada
Top 10 Insider Purchases Last Month - Insider Monkey
(RCUS) Investment Analysis - Stock Traders Daily
Arcus Biosciences at Leerink’s Global Healthcare Conference: Strategic Advancements By Investing.com - Investing.com Canada
RCUS stock touches 52-week low at $9.42 amid market challenges - Investing.com Australia
Terry Rosen Increases Stake in Arcus Biosciences Inc (RCUS) with Recent Share Purchase - GuruFocus.com
Little Excitement Around Arcus Biosciences, Inc.'s (NYSE:RCUS) Revenues As Shares Take 26% Pounding - Simply Wall St
Arcus Biosciences (RCUS): Among Stocks With At Least $10 Million In Insider Spending Recently - Insider Monkey
10 Stocks With At Least $10 Million In Insider Spending Recently - Insider Monkey
Insider Buying: Arcus Biosciences Co-Founder Bought US$201k Of Shares - Yahoo Canada Finance
Learn to Evaluate (RCUS) using the Charts - Stock Traders Daily
Arcus Biosciences (NYSE:RCUS) Upgraded at HC Wainwright - Defense World
Wedbush Forecasts Arcus Biosciences’ Q1 Earnings (NYSE:RCUS) - Defense World
Arcus Biosciences director Yasunori Kaneko buys $201,200 in shares By Investing.com - Investing.com South Africa
Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo
What is Leerink Partnrs’ Forecast for RCUS Q1 Earnings? - Defense World
Arcus Biosciences CEO Terry J. Rosen buys $201,465 in common stock - Investing.com Australia
Arcus Biosciences CEO Terry J. Rosen buys $201,465 in common stock By Investing.com - Investing.com South Africa
Arcus Biosciences director Yasunori Kaneko buys $201,200 in shares - Investing.com India
Arcus Biosciences Executives Increase Their Holdings - TradingView
RCUS stock touches 52-week low at $9.88 amid market challenges - Investing.com
RCUS stock touches 52-week low at $9.88 amid market challenges By Investing.com - Investing.com South Africa
Arcus Biosciences’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com South Africa
HC Wainwright & Co. Upgrades Arcus Biosciences (RCUS) - Nasdaq
Can Arcus Biosciences Reveal New Cancer Pipeline Updates at March Healthcare Conferences? - StockTitan
Arcus Biosciences' SWOT analysis: promising pipeline drives stock outlook - Investing.com
Arcus Biosciences’ SWOT analysis: promising pipeline drives stock outlook - Investing.com India
Arcus Biosciences gains after H.C. Wainwright upgrades to "buy" - TradingView
HC Wainwright Upgrades Arcus Biosciences to Buy From Neutral, Adjusts Price Target to $24 From $18 - Marketscreener.com
Arcus Biosciences stock rating upgraded to Buy at H.C. Wainwright By Investing.com - Investing.com UK
Arcus Biosciences Reports 2024 Financial Results and Pipeline Progress - TipRanks
Arcus Biosciences reports Q4 EPS ($1.03), consensus ($1.20) - TipRanks
Arcus Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - MarketScreener
Arcus Biosciences earnings beat by $0.20, revenue topped estimates - Investing.com Canada
Arcus Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings Flash (RCUS) Arcus Biosciences Posts Q4 Revenue $36M, vs. FactSet Est of $29.3M - Marketscreener.com
Can Arcus Biosciences' Promising Cancer Drug Results Transform Kidney Cancer Treatment? - StockTitan
Finanzdaten der Arcus Biosciences Inc-Aktie (RCUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
10.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):